The Addario Lung Cancer Medical Institute (ALCMI) today announced the appointment of Richard Erwin to the ALCMI Board of Directors, effective February 25, 2025. Erwin was also named as the research organization's Chief Operating Officer.
New partnership brings together AI experts and lung cancer researchers to improve early disease detection
GO2 for Lung Cancer (GO2), Dana-Farber Cancer Institute (Dana-Farber), and the Addario Lung Cancer Medical Institute (ALCMI), announced a major expansion of landmark research studying genetic risk for developing lung cancer.
The Addario Lung Cancer Medical Institute (ALCMI) has launched the SPARK Study to help researchers better understand treatment resistance in patients with KRAS-positive lung cancer and other cancer types.
